Pharma News — Industry Headlines for Field Reps
106 articles covering FDA approvals, layoffs, M&A, drug pricing, and pipeline updates.
Latest Articles
- ACIP's new charter raises fresh questions for vaccine field teams about credibility, coverage, and future recommendations — FieldPulse Editorial · June 25, 2026
- Cassidy's 340B bill puts hospital access and pricing conversations back at the center for pharma field teams — FieldPulse Editorial · June 25, 2026
- FDA approval gives Gilead and Merck a new first-line TNBC story with Trodelvy plus Keytruda — FieldPulse Editorial · June 25, 2026
- Pfizer gets a new niche oncology message as Ibrance wins US approval in double-positive breast cancer — FieldPulse Editorial · June 25, 2026
- Eli Lilly's July 1 Medicare GLP-1 bridge launch could reset obesity access conversations — FieldPulse Editorial · June 25, 2026
- Gilead's Trodelvy wins broad first-line TNBC approval and changes the oncology field conversation — FieldPulse Editorial · June 24, 2026
- Florida's CVS Caremark probe is early, but field and access teams should still watch it — FieldPulse Editorial · June 24, 2026
- Pfizer gives Ibrance its first breast cancer label expansion in seven years — FieldPulse Editorial · June 24, 2026
- Libtayo picks up a small but real UK access win in cervical cancer — FieldPulse Editorial · June 24, 2026
- Padcev and Trodelvy notch new EU oncology wins that field teams will have to answer for — FieldPulse Editorial · June 24, 2026
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study — FieldPulse Editorial · June 24, 2026
- MSD's TL1A drug tulisokibart delivers in pivotal IBD trial — FieldPulse Editorial · June 24, 2026
- Hospitals irate after Eli Lilly follows through on 340B ultimatum — FieldPulse Editorial · June 24, 2026
- Hospitals irate after Eli Lilly follows through on 340B ultimatum — FieldPulse Editorial · June 23, 2026
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study — FieldPulse Editorial · June 23, 2026
- MSD's TL1A drug tulisokibart delivers in pivotal IBD trial — FieldPulse Editorial · June 23, 2026
- Pfizer's Seagen-derived ADC pipeline suffers a setback — FieldPulse Editorial · June 23, 2026
- US launches probe of German 'underpayment' for medicines — FieldPulse Editorial · June 23, 2026
- Sanofi's type 1 diabetes-delaying drug cleared for NHS use — FieldPulse Editorial · June 23, 2026
- Sanofi gets an EU win in SPMS while the US path stays unresolved — FieldPulse Editorial · June 23, 2026
- Merck posts first phase 3 TL1A win in ulcerative colitis and puts the IBD field on notice — FieldPulse Editorial · June 22, 2026
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs — FieldPulse Editorial · June 22, 2026
- Pfizer's Seagen-derived lung cancer ADC misses the main phase 3 survival bar — FieldPulse Editorial · June 22, 2026
- Lilly's 340B cutoff is now an account-level access issue for hospital-facing field teams — FieldPulse Editorial · June 22, 2026
- Biogen Adds More Immune Drugs in $1B Buyout of Secretive Startup RayThera — FieldPulse Editorial · June 18, 2026
Talk · Companies